Sepsis: Antimicrobial Therapy by Finkelstein, Renato & Oren, Ilana
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books










© 2012 Finkelstein and Oren, licensee InTech. This is an open access chapter distributed under the terms of 
the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
Sepsis: Antimicrobial Therapy 
Renato Finkelstein and Ilana Oren 
Additional information is available at the end of the chapter 
http://dx.doi.org/10.5772/51714 
1. Introduction 
Twenty years ago a consensus committee of experts proposed standardized terminology 
and definitions for sepsis, organ failure, bacteremia, systemic inflammatory response 
syndrome (SIRS) and other related clinical conditions (1). Nevertheless, these terms are still 
a source of confusion and very often used interchangebly in clinical pratice.Whatever will be 
the accepted definition, sepsis is a clinical syndrome that complicates severe infection. 
However, in terms of antimicrobial therapy, diagnosing sepsis is not sufficient. The 
approach to the patient with sepsis includes also a tremendous challenge of establishing the 
etiologic agent, the anatomical site, the extent of the infectious problem and the possible 
underlying disease associated with the infection. Approximately 10 percent of patients with 
sepsis do not receive prompt antibiotic therapy for the implicated pathogen, and the 
mortality rate is 10 to 15 percent higher for such patients than for those who receive prompt, 
appropriate antibiotic therapy (2-3). Overall mortality from severe sepsis or septic shock 
ranges from 30% to 60% despite aggressive medical care (5-6). In the presence of septic 
shock, each hour delay in achieving administration of effective antibiotics is associated with 
a measurable increase in mortality (7). Therefore, antimicrobial therapy plays a central role 
in the management of these patients and the importance of the initial empiric regimen 
cannot be underestimated. The approach to critically ill patients with a suspected severe 
infection includes a well-accepted willingness to begin empirical broad-spectrum antibiotic 
therapy before the microbiological results are obtained. Intravenous antibiotic therapy 
should be started as early as possible and within the first hour of recognition of severe 
sepsis or septic shock. Appropriate cultures should be obtained before initiating antibiotic 
therapy, but should not prevent prompt administration of antimicrobial therapy. These 
recommendations are also emphasized in the recent guidelines for management of severe 
sepsis and septic shock (8). Nevertheless, even the broadest antibiotic regimen cannot 
“blindly” cover all pathogens responsible for sepsis and the choice of the initial 
antimicrobial therapy in sepsis should be guided by a systematic bedside evaluation, paired 
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with a judicious use of laboratory methods and other medical technologies. This will 
facilitate to determine the suspected focus of primary infection, one of major determinants 
in the choice of antibiotics. The antibiotic regimen should be selected taking in consideration 
the most common pathogens causing infections at these sites. However, even for the same 
site of infection choices are frequently different depending whether infections are 
community-acquired or health care-associated. The site of infection (e.g. central nervous 
system, endocardium) is also important when considering other factors such as 
pharmacokinetics, dosing and bactericidal properties of antimicrobial drugs. Other 
important factors such as knowledge of local endemic diseases, microbiological data and 
patterns of resistance increase the likelihood of prescribing appropriate antimicrobial 
therapy. Based on these principles, this review will focus on the antimicrobial therapy for 
the most common causes of sepsis and, in particular, discuss the most appropriate choices to 
be used until the causative organism and its antibiotic susceptibilities are defined. 
2. Common clinical conditions and pathogens associated with sepsis 
2.1. Severe community-acquired pneumonia 
Several large series of patients with severe sepsis have shown that the lungs are the most 
commonly identified site of primary infection (9-11).Pneumonia is among the top ten most 
common causes of death among all age groups in the United States, the sixth leading cause 
of death in those 65 years or older, and the single most common cause of infection-related 
mortality (12). Although the majority of patients with community-acquired pneumonia 
(CAP) are treated as outpatients, approximately 10% of patients with community-acquired 
pneumonia will develop severe disease, as defined by admission to an intensive care unit 
(ICU) due to the presence of shock requiring vasopressors or respiratory failure requiring 
mechanical ventilation (13). This population represents the greatest proportion of 
pneumonia-related mortality and healthcare expenditure occurs among the patients who are 
hospitalized. Using a pathophysiological approach to characterize the causes of clinical 
failure, it was found that severe sepsis and cardiac deterioration are the main causes of 
clinical failure in hospitalized patients with CAP (14).The Infectious Diseases Society of 
America/American Thoracic Society (IDSA/ATS) Consensus Guidelines on the Management 
of Community-Acquired Pneumonia in Adults strongly recommend direct admission to an 
ICU for patients with septic shock requiring vasopressors or with acute respiratory failure 
requiring intubation and mechanical ventilation (15).The clinical challenge of treating 
community-acquired pneumonia is the large number of microbial agents that can cause 
disease, the difficulty in making a clinical and etiologic diagnosis, and the fact that no single 
antimicrobial regimen can cover all the possible etiologies. Recommendations for diagnostic 
testing remain controversial. The most clear-cut indication for extensive diagnostic testing is 
in the critically ill CAP patient. Such patients should at least have blood drawn for culture 
and an endotracheal aspirate obtained if they are intubated. Blood cultures are positive in 
only 4 to 18 of patients hospitalized with community-acquired pneumonia (16); however a 
positive blood cultures is highly specific, may allow narrowing antibiotic use, and may 
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identify the presence of unusual organisms that would not be adequately covered by routine 
empirical antibiotic coverage (17). Other difficulties in treating these patients include a long 
list of bacterial, fungal, viral, and protozoal agents that may cause severe acute CAP and 
because, by the time of presentation, evaluation rarely results in a specific etiologic 
diagnosis. Therefore, antibiotic therapy is almost always begun empirically. S. pneumoniae 
and L. pneumophila are the organisms most commonly involved in cases of severe 
pneumonia, however a large number of other microorganisms must be considered. A 
review of 9 studies that included 890 patients with CAP who were admitted to the ICU 
demonstrates that the most common pathogens in the ICU population were (in descending 
order of frequency) S. pneumoniae, Legionella species, H. influenzae, Enterobacteriaceae 
species, S. aureus, and Pseudomonas species (18).In some series, M. pneumoniae is involved in 
up to 11% of patients with community-acquired pneumonia requiring intensive care (19). 
The following empirical antibiotic treatment is the minimal recommended by the joint 
IDSA/ATS guidelines for severe CAP, i.e., patients needing hospitalization in ICU (15): 
1. β-lactam (cefotaxime, ceftriaxone, or ampicillin-sulbactam) plus either azithromycin or 
a fluoroquinolone (ciprofloxacin). For penicillin-allergic patients, a respiratory 
fluoroquinolone (levofloxacin, moxifloxacin) and aztreonam are recommended. 
2. For Pseudomonas infection, it is recommended the use of an antipneumococcal, 
antipseudomonal β-lactam (piperacillin-tazobactam, cefepime, imipenem, or 
meropenem) plus either ciprofloxacin or levofloxacin (750-mg dose) or the above β-
lactam plus an aminoglycoside (gentamicin, amikacin) and azithromycin or the above 
β-lactam plus an aminoglycoside and an respiratory fluoroquinolone. For penicillin-
allergic patients, substitute aztreonam for the above β-lactam.  
3. For community-acquired methicillin-resistant Staphylococcus aureus (MRSA) infection, 
add vancomycin or linezolid.  
Infections with the overwhelming majority of CAP pathogens will be adequately treated by 
use of the recommended empirical regimens. The emergence of methicillin-resistant S. 
aureus as a CAP pathogen and the small but significant incidence of CAP due to P. 
aeruginosa are the exceptions. Once the etiology of CAP has been identified, antimicrobial 
therapy should be directed at that pathogen; however two major issues are of concern. The 
first is whether bacteremic pneumococcal pneumonia should be treated with dual therapy. 
The second is that if the patient has concomitant pneumococcal meningitis, the efficacy of 
fluoroquinolone monotherapy is uncertain. Therefore, discontinuation of combination 
therapy after results of cultures are known is most likely safe in non-ICU patients (15). 
3. Nosocomial pneumonia 
Nosocomial pneumonia (NP), and its most serious form, ventilator-associated pneumonia 
(VAP), is a major cause of morbidity and mortality in the ICU. NP accounts for up to 25% of 
all ICU infections and for more than 50% of the antibiotics prescribed (20).In this setting, 
nearly 90% of episodes of NP occur during mechanical ventilation. Rates of VAP are related 
to the duration of mechanical ventilation and have been estimated to be 3% per day during 
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the first 5 days and 2% per day thereafter (21). NP and VAP may be caused by a wide 
spectrum of bacterial pathogens, they may be polymicrobial, and are rarely due to viral or 
fungal pathogens in immunocompetent hosts (22).Time of onset of pneumonia is an 
important epidemiologic variable and risk factor for specific pathogens and outcomes in 
patients with NP and VAP. For patients who experience onset of infection within the first 4 
days of hospitalization (early-onset VAP) and who have no risk factor for health care-related 
pneumonia or multidrug-resistant pathogens, S. pneumoniae, methicillin-susceptible S. 
aureus, H. influenzae, and antimicrobial-susceptible enteric gram-negative bacilli (e.g., 
Klebsiella pneumoniae and Enterobacter species) are the most common causative pathogens 
(22). For these patients a limited-spectrum antimicrobial therapy (i.e., ceftriaxone, a 
fluoroquinolone such levofloxacin or moxafloxacin, ampicillin/sulbactam, or ertapenem) 
may be appropriate. For patients who develop severe infection later during their hospital 
stay (late-onset VAP) additional antimicrobial-resistant bacteria (e.g., P. aeruginosa, 
Acinetobacter species, and MRSA) may also be responsible for infection (23) and a broad-
spectrum combination antimicrobial therapy should be initiated promptly, with a 
commitment to de-escalating the treatment on the basis of serial clinical and microbiologic 
data. The recommended combinations (22) include an antipseudomonal cephalosporin 
(cefepime, ceftazidime), an antipseudomonal carbapenem(imipenem, meropenem), 
particularly when an extended-spectrum β-lactamase-positive strain is suspected, or a β-
lactam/β-lactamase inhibitor (piperacillin–tazobactam) plus either an antipseudomonal 
fluoroquinolone (ciprofloxacin or levofloxacin) or an aminoglycoside (amikacin, gentamicin, 
or tobramycin) plus either vancomycin or linezolid (if MRSA risk factors are present or there 
is a high incidence locally). If an aminoglycoside is one of the agents used instead of 
quinolones, a macrolide (e.g. azithromycin) should also be given if Legionella pneumophila is 
suspected. Ultimately, the choice of agent should be based on ICU-specific trends in 
pathogens and their susceptibility patterns. VAP due to multiple drug-resistant 
microorganisms is one of the most dreadful complications that occurs in critically ill patients 
and, in this setting, infections caused by carbapenem-resistant A. baumannii and K. 
pneumoniae are of special concern because very few treatment options exist. If VAP caused 
by these pathogens are considered, polymyxyns (e.g. colistin) appears to be a safe and 
effective alternative (24). A recent prospective, randomized trial has demonstrated that 
fixed-dose of linezolid was more effective than a dose-optimized vancomycin regimen for 
treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia, although the 
60-day mortality was similar (25). Cases of non-nosocomial health care-associated 
pneumonia, defined as pneumonia occurring within 48-72 hours of hospitalization in a 
patient with extensive contact with the health care system (e.g. nursing home residence, 
hemodialysis dependence, recent hospitalization), are treated with the same regimens 
recommended for NP.  
4. Urinary tract infection 
The term urosepsis is commonly used to describe the sepsis syndrome caused by urinary 
tract infection (UTI). In large series of patien
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to be source of infection in approximately 10% to 22 % of cases (9, 11). Sepsis is much more 
likely to occur among patients with upper UTI and complicated UTI, the latter defined as 
infection that occurs in a urinary tract with functionally, metabolically, or anatomically 
abnormalities (26). Infections occurring in patients with indwelling catheters and calculi, 
infection in men, pregnant women, children, and in patients who are hospitalized or in 
health care–associated settings also may be considered complicated (27). However, sepsis 
may be also a clinical presentation of acute uncomplicated pyelonephritis in young women 
(26). UTI in some adult patients groups, such as those with spinal cord injury, long-term 
catheterization, or diabetes, may progress to severe, life threatening pyelonephritis, abscess 
formation, or septicemia (28). In contrast to other community and nosocomial infections, 
there have been few new pathogens identified as important causes of UTI. E. coli accounts 
for approximately 80% of uncomplicated UTI (28); however, a broad range of bacteria can 
cause nosocomial UTI, and many are resistant to multiple antimicrobial agents. E. coli, 
although significantly less prevalent than in uncomplicated UTI, is still the most common 
cause of nosocomial bacteriuria in medical-surgical ICUs. Other gram-negative bacteria such 
as Klebsiella spp., Serratia spp., Citrobacter spp., Enterobacter spp., Pseudomonas aeruginosa, and 
gram-positive cocci, including coagulase negative staphylococci and Enterococcus spp., cause 
most of the other infections (29, 30). In patients with nosocomial UTI in medical-surgical 
ICUs reported in the U.S. National Nosocomial Infection Surveillance System from 1992 to 
1998, C. albicans constituted 15.3% and all fungal isolates 31.2% of all urinary isolates (30). 
Urosepsis, in general, is easily diagnosed by positive urine and blood cultures with the same 
pathogens, but until microbiological results are available, empirical treatment should be 
selected considering the pharmacokinetics of the agent, its spectrum of activity relative to 
the anticipated pathogens and potential for adverse effects. Therapeutic management for 
uncomplicated infection has been compromised by increasing antimicrobial resistance, 
particularly global dissemination of the CTXM-15 extended spectrum β-lactamase (ESBL) 
producing Escherichia coli ST-131 strain (31).Guidelines developed by the Infectious 
Diseases Society of America (IDSA) and the European Society for Microbiology and 
Infectious Diseases (ESCMID) (32) recommends that women with pyelonephritis requiring 
hospitalization may be initially treated with an intravenous antimicrobial regimen, such as a 
fluoroquinolone (ciprofloxacin, ofloxacin) when the prevalence of resistance of community 
uropathogens is not known to exceed 10%. If the prevalence of fluoroquinolone resistance is 
thought to exceed 10%, an initial intravenous dose of a long-acting parenteral antimicrobial, 
such as ceftriaxone or a consolidated 24-h dose of an aminoglycoside (gentamicin), with or 
without ampicillin, an aminoglycoside (gentamicin), with or without ampicillin or an 
extended-spectrum penicillin (piperacillin, mezlocillin), with or without an aminoglycoside, 
or a carbapenem (imipenem, meropenem) is recommended. Patients with community-
acquired urosepsis may be managed in a similar manner. Among patients with complicated 
nosocomial UTI the concern of multidrug resistance is much greater and the choice of 
antibiotic agent for empiric treatment should be based on available information, including 
the urine Gram-stain results, previous urine culture results, or the antimicrobial sensitivity 
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patterns of urinary pathogens isolated in the patient's hospital or long-term care facility (26, 
29). Other potential concerns with these choices include the increasing prevalence of 
resistance to fluoroquinolones in institutional settings and the frequency of enterococcal 
infections (29). In patients with nosocomial urosepsis, one should consider a broader-
spectrum drug such as piperacillin-tazobactam or a carbapenem for empiric treatment. If the 
urine Gram stain shows gram-positive cocci (most likely enterococci or staphylococci), 
treatment with vancomycin is reasonable (33). The antimicrobial regimen should be tailored 
as appropriate when the infecting strain has been identified and antimicrobial 
susceptibilities are known. 
5. Intraabdominal infections 
Intraabdominal infections (IAIs) are one of the most common causes of sepsis (9, 11) and 
they comprehend a great number of pathological conditions. According to the source, site 
and extension of the infections, IAIs may be classified in several manners (34); they may be 
retroperitoneal and intraperitoneal, primary (without an evident source) or secondary, 
diffuse or localized (peritoneal or visceral abscesses), community acquired or health care–
associated. The term complicated intra-abdominal infections is also commonly used and it 
implies an infections that extend beyond the hollow viscus of origin into the peritoneal 
space and that is associated either with abscess formation or peritonitis (35). The bacteria 
that cause intra-abdominal infections are derived from the indigenous flora of the 
gastrointestinal tract. Anaerobic bacteria are predominant in IAIs because they are the main 
component of the gastrointestinal tract flora, outnumbering aerobic and facultative bacteria 
in the ratio of 1,000 to 10,000 to one (36). Most cases of secondary peritonitis are 
polymicrobial and anaerobes play a major role (37-39).The predominant aerobic are 
Escherichia coli, Enterococcus faecalis, Klebsiella spp., Enterobacter spp., and the main anaerobic 
bacteria are anaerobic Gram-negative bacilli (including Bacteroides fragilis group and 
pigmented Prevotella and Porphyromonas), Peptostreptococcus, and Clostridium spp. (40). 
Recently, an Expert Panel of the Surgical Infection Society and the IDSA prepared guidelines 
intended for managing patients with IAIs (41). These guidelines make therapeutic 
recommendations on the basis of the severity of infection, which is defined for these 
guidelines as a composite of patient age, physiologic derangements, and background 
medical conditions. Many of these recommendations, intended for patients with severe 
infection or those considered at risk of complications, are also relevant for patients with IAI 
and sepsis and they are summarized as follow: 
1. Appropriately collected, anaerobic and aerobic cultures should be performed. These 
include blood cultures and specimen collected from the intra-abdominal focus of 
infection which are representative of the material associated with the clinical infection. 
2. Appropriate source control procedures are essential for nearly all patients with IAIs. 
These procedures include drainage of infected foci, control of ongoing peritoneal 
contamination by diversion or resection, and repair of anatomic and physiological 
function to the extent feasible. 
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3. The recommended empirical antibiotic treatment of adult patients with severe 
community-acquired infection and all patients with health care-associated infections are 
similar and should include antimicrobial regimens with broad-spectrum activity against 
gram-negative organisms, including an carbapenem (meropenem, imipenem, 
doripenem), or piperacillin-tazobactam (all with excellent antianaerobic activity), or 
ceftazidime or cefepime in combination with metronidazole (also excellent 
antianaerobic activity). Quinolones (ciprofloxacin, levofloxacin) in combination with 
metronidazole also may be used for empirical treatment if hospital surveys indicate 
>90% susceptibility of E. coli to this class of drugs. Aztreonam plus metronidazole is an 
alternative, but addition of an agent effective against gram-positive cocci is 
recommended.  
4. The empiric use of agents effective against enterococci, particularly against Enterococcus 
faecalis is also recommended in this situation and includes drugs such as ampicillin, 
piperacillin, piperacillin-tazobactam, or vancomycin. 
5. Empiric use of vancomycin should be provided to patients with health care-associated 
intra-abdominal infection who are known to be colonized with MRSA or who are at risk 
of having an infection due to this organism because of prior treatment failure and 
significant antibiotic exposure. 
6. Antifungal therapy is not routinely included in the empiric regimen, unless gram-stains 
or cultures indicate that these organisms may be involved in the infection. In this case, 
patients with sepsis should be treated with an echinocandin (caspofungin, micafungin, 
or anidulafungin) 
7. All antimicrobial therapy should be tailored when culture and susceptibility reports 
become available. 
6. Skin and soft tissue infections 
The spectrum of manifestations skin and soft tissue infections (SSTI) is wide, varying from 
otherwise healthy people with severe infection and sepsis to patients with major co-
morbidities and relatively minor infection; patients with extensive cellulitis and systemic 
symptoms who can be managed with antibiotics alone to patients with necrotizing limb-
threatening infection that requires life-saving surgery. SSTIs have been classified in several 
manners, including according to the anatomical site of infection (42), to their microbial 
etiology or by severity (43), or clinical characteristics (44). SSTIs may be caused by a large 
number of microorganisms. Therefore, in establishing a diagnosis, it is critical to ask patients 
about animal exposure, travel history, underlying diseases, recent trauma, bites, burns, and 
water exposure; and to recognize the signs of different types of infection in an effort to limit 
the spectrum of causes to a more reasonable differential diagnosis. Eron et al. (45) classify 
these infections according to the severity of local and systemic signs, thereby developing a 
system that guides the clinical management and treatment decisions for patients with SSTIs. 
Accordingly, class 4 in this classification includes sepsis syndrome and life-threatening 
infection (e.g. necrotizing fasciitis), the most serious presentations of complicated SSTI. A 
discussion on all causes of SSTIs is beyond the scope of this chapter. Instead, we will focus 
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our discussion only on necrotizing fasciitis (NF), probably the most important clinical 
presentation of complicated SSTI associated with sepsis. NF (44, 46), is a relatively rare but 
often life-threatening necrotizing infection of subcutaneous tissue and fascia. About 20% of 
patients have no visible skin lesion. In others, the initial presentation may be a trivial lesion 
or that of cellulitis, which can advance very rapidly. Clinical signs that the process involves 
the deeper tissue planes include failure to respond to initial antibiotic therapy, a hard, 
wooden feel of the subcutaneous tissue, altered mental status, bullous lesions and skin 
necrosis or ecchymoses. According to the microbiological characteristics, NF has two major 
types. In type I, the polymicrobial form (most originating from the bowel flora), up to 15 
different anaerobic (e.g. Clostridium, Bacteroides, Prevotella, and Peptostreptococcus) and aerobic 
organisms (E. coli, Klebsiella, Proteus) may be cultured. Four major clinical settings of Type I 
NF are recognized: (1) surgical procedures involving the bowel or penetrating abdominal 
trauma, (2) decubitus ulcer or a perianal abscess, (3) at the site of injection in injection drug 
users, and (4) spread from a Bartholin abscess or a minor vulvovaginal infection. 
Nevertheless, some cases are caused by a single pathogen, particularly anaerobic 
Streptococcus species. Type II NF is monomicrobial and classically has been caused by Group 
A Streptococcus (GAS) (Streptococcus pyogenes). Most cases of NF caused by GAS (also 
known as hemolytic streptococcal gangrene, “flesh-eating disease”) are community acquired 
and present in the limbs. An underlying cause (e.g. diabetes, peripheral vascular disease) is 
common. Cases of NF that arise after varicella or trivial injuries are almost always due to S. 
pyogenes. The mortality in this group is high, approaching 50%–70% in patients with 
hypotension and organ failure (44).Other causes of NF are: V. vulnificus, A. hydrophila, 
anaerobic streptococci (i.e., Peptostreptococcus species), and community-acquired MRSA (47). 
A definitive bacteriologic diagnosis is best established by culture of tissue specimens 
obtained during operation or by positive blood culture results. Aggressive surgical 
intervention is the major therapeutic modality in cases of necrotizing fasciitis. Antimicrobial 
therapy must be directed at the pathogens and several antibiotic choices for treating NF (44) 
are summarized as follow: 
1. Treatment of polymicrobial NF must include agents effective against both aerobes and 
anaerobes. Choices include: a) ampicillin which may cover susceptible enteric aerobic 
organisms (e.g. E. coli) and gram-positive organisms, such as Peptostreptococcus species, 
group B, C, or G streptococci, and some anaerobes; b) clindamycin which is useful for 
coverage of anaerobes and aerobic gram-positive cocci, including most S. aureus 
serogroups; c) metronidazole which has the greatest anaerobic spectrum against the 
enteric gram-negative anaerobes (but it is less effective against the gram-positive 
anaerobic cocci); d) gentamicin or a fluorquinolone (ciprofloxacin), ticarcillin-
clavulanate, or piperacillin-tazobactam, which may cover resistant gram-negative rods. 
The practice guidelines of the Infectious Diseases Society of America for treating NF 
consider a combination of ampicillin-sulbactam plus clindamycin plus ciprofloxacin as 
the best choice of antibiotics for community-acquired mixed infections (44). 
2. Necrotizing fasciitis caused by group A streptococci should be treated with clindamycin 
and penicillin. 
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3. A history of water exposure or fish injury or handling in a patient with NF is typical of 
infections caused by A. hydrophila, and, in particular, V. vulnificus, the most common 
recognized marine pathogen of SSTIs. A combination therapy with cefotaxime or 
ceftazidime (which are also recommended for treating infections due to Aeromonas 
infection) and minocycline is suggested for treating adult patients with bacteremia and 
severe soft-tissue infection caused by V. vulnificus (48). 
4. S. aureus, particularly MRSA, is the most common Gram-positive aerobe cause of 
complicated SSTIs. The increased prevalence of hospital-acquired MRSA has been 
noted worldwide and more recently also in the community setting (CA-MRSA) (46). 
In the Unites States, the predominant CA-MRSA clone is USA300 which has caused 
several numerous outbreaks including prison innmates, professional football players 
and others populations (46). Therefore, the IDSA guidelines for the management of 
patients with MRSA infections (49), recommend that empirical therapy for MRSA 
should be considered pending culture data in adult hospitalized patients with 
complicated SSTI (deeper soft-tissue infections, surgical/traumatic wound infection, 
major abscesses, cellulitis, and infected ulcers and burns). In addition to surgical 
debridement and broad-spectrum antibiotics these recommendations include the 
following options: intravenous vancomycin, oral or intravenous linezolid 600 mg 
twice daily, daptomycin 4 mg/kg/dose IV once daily, telavancin 10 mg/kg/dose IV 
once daily, and clindamycin 600 mg IV or PO 3 times a day. A β-lactam antibiotic 
(e.g. cefazolin) may be considered in hospitalized patients with nonpurulent cellulitis 
with modification to MRSA-active therapy if there is no clinical response. Seven to 14 
days of therapy is recommended but should be individualized on the basis of the 
patient's clinical response. Obviously, the oral route is not recommended for septic 
patients. 
7. Neutropenic fever 
Fever occurs frequently during chemotherapy-induced neutropenia: about 30% of patients 
with solid tumors and > 80% of those with hematological malignancies will develop fever 
during at least one of the chemotherapy cycles associated with neutropenia (50). Mortality 
rate of sepsis in neutropenic patients is extremely high. Bacteremia occurs in 10-15% of all 
patients, with most episodes occurring in the setting of prolonged and profound 
neutropenia (absolute neutrophil count < 100) (51-53). Substantial fluctuations in the 
epidemiologic spectrum of bloodstream infections have occurred over the past 40 years. 
Early in the development of cytotoxic chemotherapy, during the 1960s and 1970s, gram-
negative pathogens, particularly E. coli, Klebsiella spp., Enterobacter spp., Pseudomonas 
aeruginosa and Stenotrophomonas spp., predominated. In the 1980s and 1990s, gram-
positive organisms became more common, because of the increasing use of indwelling 
intravenous catheters (53-58). Nowadays, there is again a trend toward a predominance of 
infections caused by gram-negative pathogens and in particular those due to multidrug-
resistant (MDR) bacteria. Extended spectrum beta-lactamase (ESBL) producing gram-
negative rods, especially Klebsiella and Enterobacter species, are sometimes susceptible 
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only to carbapenems (59-60). Carbapenemase-producing Klebsiella and Pseudomonas 
species emerged recently and cause infections that are resistant to carbapenems (61). 
However, severe infections caused by gram-positive resistant pathogens such as MRSA 
and vancomycin-resistant Enterococcus (VRE), or penicillin resistant pneumococci and 
viridans streptococci are still prevalent in certain centers (62-64). An update which is 
intended as guidelines for the use of antimicrobial agents in managing patients with 
cancer who experience chemotherapy-induced fever and neutropenia was recently 
published by the IDSA (65). Accordingly, patients presenting with fever and neutropenia 
should receive empirical antibiotic therapy immediately after the initial clinical evaluation 
and after appropriate cultures are obtained. The initial empiric antibiotic treatment 
recommended for high risk patients with neutropenia, is monotherapy with an 
antipseudomonal beta-lactam agent, such as cephalosporin (cefepime), or a carbapenem 
(imipenem, meropenem), or a penicillin drug (piperacillin/tazobactam). Addition of an 
aminoglycoside (gentamicin, amikacin) as a combination therapy has not been proven 
beneficial in a meta-analysis of numerous trials (66). Modifications in the above regimens 
should be considered according to local epidemiological data and patient’s specific risk 
factors. For instance, vancomycin, linezolid or daptomycin should be considered in the 
initial management of patients known to be colonized or previously infected with MRSA 
or VRE; for patients previously infected or colonized with ESBL-producing gram-negative 
rods, one should consider the early use of a carbapenem; colonization with carbapenem-
resistant Enterobacteriacea (CRE) may justify the addition of drugs such as colistin or 
tigecycline. Empirical antibiotics are considered vital in febrile neutropenic patients. 
Although up to 23% of these episodes are associated with bacteremia (67), treatment 
should be continued even if blood cultures remain negative. Finally, high risk patients 
who have received intensive cytotoxic chemotherapy are at risk for invasive fungal 
infection. Yeasts which cause bloodstream infections (primarily Candida species), and 
molds which cause sino-pulmonary infections (primarily Aspergillus species) typically 
cause infections which are manifested by persistent or recurrent fever in patients with 
prolonged neutropenia, rather than causing initial fever in the course of neutropenia (68). 
Empirical antifungal coverage should be considered in high-risk patients after 4-7 days of 
a broad-spectrum antibacterial regimen and no identified fever source. For over 3 
decades, amphotericin B was the drug used for empiric antifungal treatment, based on a 
study of Pizzo et al (69) which showed decrease mortality associated with this practice. In 
the last decade, a number of trials have identified roles for other antifungal agents with 
anti-yeast and anti-mold activity, like lipid formulations of amphotericin B, or 
echinocandins (caspofungin) and broad spectrum azoles (voriconazole), based on their 
lower toxicity compared to traditional amphotericin B (70-74). 
8. Catheter related bloodstream infections (CRBSI) 
Approximately 80,000 CRBSIs occur in ICUs every year (75). CRBSI is defined when 
bacteremia or fungemia occurs in a patient who has an intravascular device and a positive 
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blood culture obtained from a peripheral vein, clinical manifestation of infection, and no 
apparent source for bloodstream infection other than the catheter. A positive result of 
semiquantitative catheter tip culture (>15 cfu) with the same pathogen, or of simultaneous 
quantitative blood cultures obtained from catheter and peripheral blood (ratio of >3:1 cfu/ml 
of blood, respectively) or differential time to positivity (≥ 2 hours) between catheter and 
peripheral vein blood culture are also required for this the definition (76). Gram staining 
routine culture with additional culture for fungi and acid-fast organisms as indicated, 
obtained from any exudate at the insertion site of the catheter, are important diagnostic 
tools, particularly when assessing immunocompromised patients. Several characteristics are 
associated with an increased risk of CRBSI with the most important being the type of the 
intravascular device (short-term central venous catheters are at the highest risk) (77), the 
intended use of the catheter (e.g. for total parenteral therapy nutrition use), the insertion site 
(femoral site at highest risk), the frequency with which the catheter is accessed, the 
characteristics of the patient, the experience of the individual who installs the catheter and 
the use of proven infection control measures (78-79). The pathogens that most commonly 
cause CRBSI differ a little according to the catheter type. In order of prevalence, the 4 groups 
of microbes that most commonly cause CRBSI associated with percutaneously inserted, 
noncuffed catheters are as follows: coagulase-negative staphylococci, S. aureus, Candida 
species, and enteric gram-negative bacilli. For surgically implanted catheters and 
peripherally inserted CVCs, they are coagulase-negative staphylococci, enteric gram-
negative bacilli, S. aureus, and P. aeruginosa (79). The following discussion includes current 
recommendations for the management of CRBSI as updated by the IDSA in 2009 and 
emphasizes the most important aspects relevant to patients with CRBSI and sepsis (76). 
Most situations involving patients with CRBSI and sepsis require the removal of the 
catheter. Exceptions for this rule are patients with limited access sites and uncomplicated 
CRBSI involving long-term catheters (e.g., patients undergoing hemodialysis) due to 
pathogens other than S. aureus, P. aeruginosa, Bacillus species, Micrococcus species, 
Propionibacteria, fungi, or mycobacteria. In these patients treatment may be attempted 
without catheter removal, with the use of both systemic and antimicrobial lock therapy if 
there is a prompt response to antibiotic therapy (80, 81). The antibiotic lock should be 
changed every 24-48 hours. The concentration of the antibiotic in the lock solution should be 
at least 1000 times higher than the MIC of the microorganism treated (82). Although a 
declining incidence, MRSA represents approximately 7.5% of all reported ICU central line-
associated bloodstream infections (83). In addition, coagulase-negative staphylococci are the 
most common cause of catheter-related infection. Most of these pathogens exhibit 
methicillin resistance, and this should be considered when choosing empirical therapy for 
catheter-related infection (84-85). Consequently, vancomycin should be recommended for 
the initial empiric antibiotic regimen of patients with CRBSI and sepsis. This regimen should 
include coverage for gram-negative bacilli using a fourth-generation cephalosporin 
(cefepime), or a carbapenem (imipenem, meropenem), or a beta-lactam/beta-lactamase 
inhibitor combinations (piperacillin/tazobactam), with or without an aminoglycoside 
(gentamicin, tobramicin, amikacin). Based on local antimicrobial epidemiologic and 
susceptibility data, empirical coverage for multidrug resistant gram-negative bacilli with 
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additional drugs (e.g. colistin) may also be considered. A fungal etiology, mainly invasive 
Candida infection, should be suspected in septic patients with any of the following risk 
factors: TPN administration, prolonged use of broad-spectrum antibiotics, hematologic 
malignancy, femoral catheterization, or colonization with candida species in multiple sites 
(86, 87). An echinocandin (caspofungin, anidulafungin) is the recommended empirical 
treatment for patients with recent azole exposure, patients with moderately severe to severe 
illness, or patients who are at high risk of infection due to C. glabrata or C. krusei (88). 
Therefore, this class of drugs should be preferred for the empirical treatment when sepsis is 
present. Transition to fluconazole is recommended for patients who have isolates 
susceptible to fluconazole (e.g.,Candida albicans) and who are clinically stable. Duration of 
treatment depends on the pathogen involved. CRBSI caused by coagulase-negative 
staphylococci should be treated for 5-7 days if the catheter is removed, and for 10-14 days in 
combination with antibiotic lock therapy, if the catheter is retained. S. aureus CRBSI should 
be generally treated for 4-6 weeks. A short duration of treatment (minimum of 14 days) can 
be considered in the absence of following conditions: a) diabetes mellitus; b) 
immunosuppression; c) prosthetic intravascular devices or grafts; d) endocarditis or 
suppurative thrombophlebitis; e) metastatic infection. The same approach may be adopted if 
fever and bacteremia resolved after 72 hours of treatment or if the infected catheter was 
removed. 
9. Conclusion 
Sepsis is a clinical syndrome that complicates severe infection and is associated with high 
mortality rates despite aggressive medical care. Antimicrobial therapy plays a central role in 
the management of these patients. Early institution of empirical but appropriate antibiotic 
treatment can influence the outcome and this is optimally done through a systematic 
bedside clinical evaluation, paired with a judicious use of laboratory methods and other 
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